cbdMD, Inc. Earnings Recaps
Q3 2026
May 17, 2026
Shares fell 3.6% after cbdMD reported significant margin pressure and cautious near-term outlook driven by integration costs from the Bluebird acquisition and accelerated investment in the new CMS substance access channel. Investors questioned the sustainability of growth given ongoing regulatory headwinds and the near-term negative earnings impact.
Key takeaways
- Revenue grew 19% year-over-year to $5.6 million, with a 12% sequential increase, driven partly by the recent Bluebird Botanicals acquisition.
- Core cbdMD business excluding Bluebird showed modest growth of $0.5 million year-over-year and $0.3 million sequentially, the highest quarterly revenue since December 2023.
- Wholesale channel expanded strongly, up 65% year-over-year to 33% of total revenue, led by cbdMD brand and Oasis TSC beverage.
- The Bluebird acquisition incurred transition and integration costs in Q2, suppressing earnings, though March saw positive contribution beginning.
- Accelerated investment in the CMS Medicare beneficiary engagement initiative created near-term expenses, delaying revenue realization, with management emphasizing a longer 12-18 month horizon for payoffs amid ongoing state regulatory volatility.
Q2 2026
May 16, 2026
Shares of cbdMD declined 3.6% after earnings, reflecting investor disappointment with margin pressures and elevated near-term costs related to the accelerated CMS substance access pathway rollout and integration expenses from the Bluebird Botanicals acquisition.
Key takeaways
- Net sales grew 19% year-over-year to $5.6 million and 12% sequentially, with core business growth excluding Bluebird adding approximately $0.5 million vs. prior year and $0.3 million sequentially.
- Direct-to-consumer accounted for 67% of revenue while wholesale grew 65% year-over-year, reaching 33% of total sales, supported by both cbdMD and Oasis TSC beverage brands.
- The Bluebird Botanicals acquisition, closed in mid-January, negatively impacted earnings due to transition and integration costs, though it began contributing positively in March.
- The company accelerated investments in the CMS beneficiary engagement incentive program, incurring near-term costs for a clinical and healthcare channel buildout, delaying revenue benefits to the medium term.
- Ongoing state regulatory volatility increased packaging, testing costs, and constrained product sales, adding operational complexity and expense in the short term.